Artificial expression constructs for selectively regulating gene expression in selected neuronal cell populations

Abstract

To provide artificial expression constructs for selectively modulating gene expression in selected neuronal cell populations.SOLUTION: Artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in GABAergic neurons generally; and / or GABAergic neuron cell types such as lysosomal associated membrane protein 5 (Lamp5) neurons; vasoactive intestinal polypeptide-expressing (Vip) neurons; somatostatin (Sst) neurons; and / or parvalbumin (Pvalb) neuron cell types. Certain artificial expression constructs additionally drive selective gene expression in Layer 4 and / or layer 5 intratelencephalic (IT) neurons, deep cerebellar nuclear neurons or cerebellar Purkinje cells.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Patent Application No. 62 / 806,660, filed on 15 February 2019, U.S. Provisional Patent Application No. 62 / 806,686, filed on 15 February 2019, and U.S. Provisional Patent Application No. 62 / 874,859, filed on 16 July 2019, each of which is incorporated by reference in its entirety as if it were fully described herein.

[0002] Description of research and development funded by the federal government. This invention was made with government support under MH114126 and DA036909, awarded by the National Institutes of Health. The government has certain rights to this invention.

[0003] This disclosure provides artificial expression constructs for selectively regulating gene expression in selected central nervous system cell types. These artificial expression constructs can be used to selectively express synthetic genes or modify gene expression in gamma-aminobutyric acid (GABA)-gated neurons in general, and / or GABAergic neuronal cell subclasses such as lysosomal membrane protein 5 (Lamp5) neurons, vasoactive intestinal polypeptide-expressing (Vip) neurons, somatostatin (Sst) neurons, and / or parvalbumin (Pvalb) neurons. Specific artificial expression constructs further drive selective gene expression in telencephalon (IT) neurons of layer 4 and / or layer 5, or in non-neocortical neurons such as deep cerebellar nucleus Pvalb-positive neurons or cerebellar Purkinje cells. [Background technology]

[0004] To fully understand brain biology, it is necessary to distinguish and define various cell types, and to further study them, it is necessary to identify artificial expression constructs that can selectively label and disrupt them. In mice, recombinase driver lines have been used to prove highly effective in labeling cell populations that share marker gene expression. [Overview of the project] [Problems that the invention aims to solve]

[0005] However, creating, maintaining, and using strains that label cell types with high specificity can be costly and frequently require triple transgenic crosses, which result in a low number of experimental animals. Furthermore, these tools require germline transgenic animals and are therefore not applicable to humans. [Means for solving the problem]

[0006] This disclosure provides artificial expression constructs that selectively drive gene expression in target central nervous system cell populations. Target central nervous system cell populations include gamma-aminobutyric acid (GABA) ergic neurons in general, and / or GABAergic neuronal cell subclasses such as lysosomal membrane protein 5 (Lamp5) neurons, vasoactive intestinal polypeptide expressing (Vip) neurons, somatostatin (Sst) neurons, and / or parvalbumin (Pvalb) neurons. Non-neocortical neurons such as telencephalon (IT) neurons in layer 4 and / or layer 5, or deep cerebellar nucleus Pvalb-positive neurons or cerebellar Purkinje cells can also be targeted for selective gene expression.

[0007] A specific embodiment of the artificial expression construct utilizes the following enhancers to selectively drive protein expression within a target central nervous system cell population as follows (enhancer / target cell population): Grik1_enhGad2-1 / GABAergic neurons in general, Grik1_enhGad2-2 / GABAergic neurons in general, mscRE5 / GABAergic neurons in general, mscRE8 / GABAergic neurons in general, eHGT_019h / Lamp5 neurons, eHGT_022h / Lamp5 and Vip neurons, eHGT_022m / Lamp5 and Vip neurons Ron, eHGT_017h / Lamp5, Vip and Sst neurons, eHGT_17m / Lamp5, Vip and Sst neurons, eHGT_079h / parvalbumin (Pvalb) neuron cell type, eHGT_082h / Pvalb neuron cell type in cortical and deep cerebellar nucleus neurons, eHGT_086h / Pvalb neuron cell type, eHGT_128h / Pvalb neuron cell type, eHGT_140h / Pvalb neuron cell type, eHGT_064h / Pvalb and Sst neuron cell type, eHGT_023h / Pvalb cell type, L4 and L5 IT neurons and Purkinje cells, as well as eHGT_359 / Pvalb cell type and cerebellar Purkinje cells.

[0008] Certain embodiments provide an artificial expression construct that includes the characteristics of the vectors described herein, including vectors: AiP1146, AiP1113, AiP1147, AiP1147, AiP1013, AiP1012, CN1525, CN1528, CN1532, CN1621, CN1633, CN1259, CN2045, CN1255, CN1408, CN1258, CN1279, CN1253, and CN1274.

[0009] Some of the drawings shown herein are better understood in color. The applicant considers the color versions of the drawings to be part of the initial submission and reserves the right to present color images of the drawings in subsequent proceedings. For example, Figures 3A, 3B, 5, 6A, 6B, 7A, 7B, 8A, 8B, 9A, 9C, 10A, 11A, 11B, 12A, 13A, 13B, 14A, 14B, 14D, 15A, 15B, 16A, 16B, 17A, 17B, 18A, 18B, 19A, 19B, 19C, and 20, described below, reflect the color-labeled assays presented as black and white images. [Brief explanation of the drawing]

[0010] [Figure 1] Summary of enhancer discovery for viral tools. To construct cell type-specific labeling tools, cells were isolated from adult mouse cortex and single-cell assays of transposase-accessible chromatin using sequencing (scATAC-seq) were performed. Samples were clustered and clusters were identified by comparison with single-cell RNA sequencing (scRNA-seq) datasets. Next, single cells matching the same transcriptome type were pooled and the genome was searched for type-specific putative enhancers. These regions were cloned upstream of minimal promoters in the AAV genome backbone used to construct self-complementary adeno-associated virus vectors (scAAV) or recombinant adeno-associated virus vectors (rAAV). These viral tools were delivered postorbitally to label specific populations of GABAergic neurons. In cell type-matched cells, the enhancers recruit their homologous transcription factors to drive cell type-specific expression. In other cells, the viral genome is present, but the transcript is not expressed. [Figure 2A]vAi30.0 (AiP1146) with Grik1_enhGad2-1 enhancer. (2A) Schematic diagram of the enhancer-containing viral vector showing all major components. ITR = terminal inversion sequence, Hsp68 = heat shock protein 68 minimal promoter, WPRE3 = woodchuck post-transcriptional regulatory element 3, BGHpA = bovine growth hormone polyA, and Grik1_enhGad2-1 = eAi12.0 (MGT_E31) enhancer. [Figure 2B] vAi30.0 (AiP1146) possessing the Grik1_enhGad2-1 enhancer. (2B) Purified AiV1146 virus was injected into the primary visual cortex of Gad2-IRES-Cre. Expression of Ai14 animals and the transgene was analyzed in fixed brain sections several weeks after injection. tdTomato labels a population of pan-GABAergic interneurons. Co-labeling of EGFP and tdTomato was observed in many cells (see merged image), confirming that this virus labels a subset of GABAergic neurons. [Figure 3A] vAi30.1 (AiP1113) possessing the Grik1_enhGad2-1 enhancer. Purified AiV1113 virus was injected into the posterior orbital sinus of C57BL / 6J wild-type mice, and EGFP expression was analyzed in fixed brain sections 2 weeks after injection. (3A) Spontaneous fluorescence and (3B) fluorescence enhanced by staining with anti-GFP antibody are shown. GFP-positive labeled neurons were scattered throughout the cortex and showed the typical spineless dendritic morphology characteristic of cortical interneurons. [Figure 3B] vAi30.1 (AiP1113) possessing the Grik1_enhGad2-1 enhancer. Purified AiV1113 virus was injected into the posterior orbital sinus of C57BL / 6J wild-type mice, and EGFP expression was analyzed in fixed brain sections 2 weeks after injection. (3A) Spontaneous fluorescence and (3B) fluorescence enhanced by staining with anti-GFP antibody are shown. GFP-positive labeled neurons were scattered throughout the cortex and showed the typical spineless dendritic morphology characteristic of cortical interneurons. [Figure 4]vAi31.0 (AiP1147) with the Grik1_enhGad2-2 enhancer. The purified AiV1147 virus was injected into the primary visual cortex of Gad2-IRES-Cre. The Ai14 animals and transgene expression were analyzed in fixed brain sections several weeks after injection. tdTomato labels the pan-GABAergic interneuron population. Co-labeling of EGFP and tdTomato was observed in many cells (see merged image), confirming that this virus labels a subset of GABAergic neurons. [Figure 5] vAi11.0 (AiP989) with the mscRE5 enhancer. The purified AiV989 virus was injected into the posterior orbital cavity of C57BL / 6J wild-type mice, and EGFP expression was analyzed in fixed brain sections 2 weeks after injection. GFP-positive neurons were observed to be scattered throughout the cortex and showed the typical spine-less dendritic morphology characteristic of cortical interneurons. Labeled neurons of a similar morphology were also observed in other subcortical brain structures. [Figure 6A] vAi12.0 (AiP1013) with the mscRE5 enhancer. (6A) The purified AiV1013 virus was injected into the posterior orbital cavity of Ai65F mice (Ai65F mice are a Flp-dependent tdTomato reporter mouse line), and tdTomato expression was analyzed in fixed brain sections 2 weeks after injection. [Figure 6B] vAi12.0 (AiP1013) with the mscRE5 enhancer. (6B) Enlarged image of the area enclosed by the square shown in Figure 6A. tdTomato-positive neurons were observed to be scattered throughout the cortex and showed the typical spine-less dendritic morphology characteristic of cortical interneurons. Labeled neurons of both similar and diverse morphologies were also observed in many other subcortical brain structures. [Figure 7A] vAi14.0 (AiP1012) with the mscRE8 enhancer. (7A) The purified AiV1012 virus was injected into the posterior orbital cavity of Ai65F mice (Ai65F mice are a Flp-dependent tdTomato reporter mouse line), and tdTomato expression was analyzed in fixed brain sections 2 weeks after injection. [Figure 7B]vAi14.0 (AiP1012) with the mscRE8 enhancer. (7B) Enlarged image of the region surrounded by the square shown in Fig. 7A. tdTomato-positive neurons were observed to be scattered throughout the cortex and showed the typical aspinous dendritic morphology characteristic of cortical interneurons. Labeled neurons of a similar morphology were also observed in many other subcortical brain structures. [Figure 8A] (8A) Fluorescent expression of CN1525 (eHGT_019h) shown in black in a sagittal section of the whole mouse brain. [Figure 8B] (8B) Natural SYFP2 fluorescence image of a fresh section of V1 shows sparse cortical labeling. [Figure 8C] (8C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to an existing classification of mouse V1 cell types. The plot shows single cells grouped by subtype. [Figure 8D] (8D) The dendrogram shows the mapping of each single cell to the terminal branches of the mouse classification, if possible. The position of each circle reflects the range (terminal branch direction) of the single-cell mapping, and the size of the circle reflects the number of single cells mapped to that point within the hierarchy. The bars protruding downward reflect the number of cells mapped to that terminal branch of the cell type classification. Note that most cells are Lamp5+. [Figure 9A] (9A) Fluorescent (white) image of CN1258 (eHGT_022h) in a fresh section of mouse V1 shows sparse cortical labeling. [Figure 9B] (9B) Quantification of three repetitions of the overlap between CN1258-driven SYFP2 expression and antibody markers of GABAergic neuron types Lamp5, Vip, Sst, and Pvalb. [Figure 9C] (9C) CN1258 labeling of human organotypic slice tissue ex vivo shows enrichment of SYFP2 in the upper layer of the neocortex, which indicates enrichment of Lamp5 and VIP cells. [Figure 9D](9D) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from human MTG (top) and mouse V1 (bottom). After single-cell gene expression analysis, cells were mapped to existing classifications of human MTG cell type or mouse V1 cell type. The plots show the mapping of each single cell to one of the classifications, as described in relation to Figure 8D. Note that the majority of cells are Lamp5+ or Vip+ for both species. [Figure 10A] (10A) The fluorescence (white) image of CN1279 (eHGT_022m) in a fresh section of mouse V1 shows sparse cortical labeling. [Figure 10B] (10B) Quantification of three repeats of overlap between CN1259-driven SYFP2 expression and antibody markers for GABAergic neuron-type Lamp5, Vip, Sst, and Pvalb. [Figure 11A] (11A) Fluorescence expression of CN1253 (eHGT_017h), shown in black in sagittal sections of the entire mouse brain. [Figure 11B] (11B) High-resolution image showing the overlap between SYFP2 fluorescence of CN1253 and mRNA expression of GABAergic markers Gad1, Sst, and Lamp5. Arrows indicate SYFP-labeled cells. [Figure 11C] (11C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to existing classifications of mouse V1 cell types, as described in relation to Figure 8D. Note that the majority of cells were Lamp5+, Vip+, or Sst+. [Figure 12A] (12A) Fluorescence expression of CN1274 (eHGT_017m), shown in black in sagittal sections of the entire mouse brain. [Figure 12B] (12B) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to existing classifications of mouse V1 cell types, as described in relation to Figure 8D. Note that the majority of cells were Lamp5+, Vip+, or Sst+. [Figure 13A](13A) Fluorescence expression of CN1525 (eHGT_079h), shown in black in sagittal sections of the entire mouse brain. [Figure 13B] (13B) High-resolution image showing the overlap between SYFP2 fluorescence of CN1525 and mRNA expression of GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 13C] (13C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to existing classifications of mouse V1 cell types, as described in relation to Figure 8D. Note that almost all cells are of the Pvalb neuron type. [Figure 14A] (14A) Fluorescence expression of CN1528 (eHGT_082h), shown in black in sagittal sections of the entire mouse brain. [Figure 14B] (14B) High-resolution image showing overlap between SYFP2 fluorescence of CN1528 and mRNA expression of GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. Arrows highlight some SYFP2+ cells. [Figure 14C] (14C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to existing classifications of mouse V1 cell types, as described in relation to Figure 8D. Note that almost all cells are of the Pvalb neuron type. [Figure 14D] (14D) Pvalb-positive glutamatergic (Gad1-negative) and GABAergic (Gad1-positive) cells of the deep cerebellar nuclei are labeled with SYFP2 after intravenous administration of CN1528 packaged by PHP.eB. [Figure 15A] (15A) Fluorescence expression of CN1532(eHGT_086h), shown in black in sagittal sections of the entire mouse brain. [Figure 15B](15B) High-resolution image showing duplication between SYFP2 fluorescence of CN1532 and mRNA of GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 16A] (16A) Fluorescence expression of CN1621(eHGT_128h), shown in black in sagittal sections of the entire mouse brain. [Figure 16B] (16B) High-resolution image showing the overlap between SYFP2 fluorescence in CN1621 and mRNA expression of the GABAergic marker Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 16C] (16C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to existing classifications of mouse V1 cell types, as described in relation to Figure 8D. Note that almost all cells are of the Pvalb neuron type. [Figure 17A] (17A) Fluorescence expression of CN1633(eHGT_140h), shown in black in sagittal sections of the entire mouse brain. [Figure 17B] (17B) High-resolution image showing the overlap between SYFP2 fluorescence of CN1633 and mRNA expression of GABAergic markers Gad1 and Pvalb. Arrows indicate SYFP2-labeled cells. [Figure 17C] (17C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to existing classifications of mouse V1 cell types, as described in relation to Figure 8D. Note that almost all cells are of the Pvalb neuron type. [Figure 18A] (18A) Fluorescence expression of CN1408 (eHGT_064), shown in black in sagittal sections of the entire mouse brain. [Figure 18B] (18B) High-resolution image showing the overlap between SYFP2 fluorescence of CN1408 and mRNA expression of GABAergic markers Pvalb or Sst. Arrows indicate SYFP2-labeled cells co-labeled with Pvalb or Sst, and asterisks indicate labeled cells not co-labeled with Pvalb or Sst. [Figure 18C] (18C) Single-cell transcriptome characterization of SYFP2 fluorescent cells isolated from mouse V1. After single-cell gene expression analysis, the cells were mapped to existing classifications of mouse V1 cell types, as described in relation to Figure 8D. Note that almost all of the recovered cells were of the Pvalb or Sst neuron type. [Figure 19A] (19A) Fluorescence expression of CN1259 (eHGT_023h), shown in black in sagittal sections of the entire mouse brain. Strong expression is observed in the neocortex and non-neocortical brain regions such as the cerebellum. [Figure 19B] (19B) High-resolution images show the overlap between SYFP2 fluorescence of CN1259 and mRNA expression of GABAergic markers Gad1, Vip, and Pvalb. Arrows indicate SYFP2-labeled cells. Note that most cells overlap with Gad1, and many cells overlap with Pvalb. [Figure 19C] (19C) Cerebellar Pvalb-positive Purkinje cells (Gad1 and Pvalb-positive) are labeled with SYFP2 after intravenous administration of CN1259 packaged in PHP.eB. [Figure 20] Fluorescence expression of CN2045 (eHGT_359h), shown in black in sagittal sections of the entire mouse brain. Expression in the cortex and hippocampus indicates Pvalb expression, and strong labeling of cerebellar Purkinje cells is present. [Figure 21A-1] (21A) A table listing the components contained in each vector sequence, summarizing the vector name and length, enhancer, promoter, product class, primary product, and other components of the vector. [Figure 21A-2] (21A) A table listing the components contained in each vector sequence, summarizing the vector name and length, enhancer, promoter, product class, primary product, and other components of the vector. [Figure 21B-1](21B) Summarize the cell type specificity of the enhancer and vector. The origin species is indicated, where H indicates human and M indicates mouse. Cell type specificity is indicated, where S = a subset of types within the group and A = all types within the group. Validation methods are indicated by * = tested and validated in mouse, RNA-seq and another modality, ~ = tested and validated in mouse and primate / human, RNA-seq and another modality, ^ = tested and validated in mouse using at least one validation method, and + = awaiting additional validation after testing. The column labeled "Validation Method" lists the validation method, where T indicates validation by tissue expression, R indicates validation by single-cell RNA-seq, I indicates validation by immunohistochemistry or mFISH, and TG indicates validation by tissue expression and gene labeling. [Figure 21B-2] (21B) Summarize the cell type specificity of the enhancer and vector. The origin species is indicated, where H indicates human and M indicates mouse. Cell type specificity is indicated, where S = a subset of types within the group and A = all types within the group. Validation methods are indicated by * = tested and validated in mouse, RNA-seq and another modality, ~ = tested and validated in mouse and primate / human, RNA-seq and another modality, ^ = tested and validated in mouse using at least one validation method, and + = awaiting additional validation after testing. The column labeled "Validation Method" lists the validation method, where T indicates validation by tissue expression, R indicates validation by single-cell RNA-seq, I indicates validation by immunohistochemistry or mFISH, and TG indicates validation by tissue expression and gene labeling. [Figure 22-1]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-2]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-3]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-4]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-5]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-6]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-7]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-8]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-9]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-10]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-11]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-12]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-13]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-14]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-15]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-16]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-17]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-18]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-19]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-20]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-21]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-22]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-23]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-24]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-25]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-26]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-27]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-28]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-29]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-30]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-31]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-32]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-33]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-34]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-35]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-36]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-37]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-38]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-39]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-40]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-41]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-42]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-43]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-44]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-45]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-46]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Figure 22-47]Sequences supplementing this disclosure. The sequences are enhancer Grik1_enhGad2-1(eAi12.0, MGT_E31)(SEQ ID NOs. 1 and 42), enhancer Grik1_enhGad2-2(eAi13.0, MGT_E65)(SEQ ID NOs. 2), enhancer mscRE5(eAi4.0, MGT_E5)(SEQ ID NOs. 3), enhancer mscRE8(eAi5.0, MGT_E8)(SEQ ID NOs. 4), enhancer eHGT_079h(eAi115.0)(SEQ ID NOs. 5), enhancer eHGT_082h(eAi116.0)(SEQ ID NOs. 6), enhancer eHGT_086h(eAi117.0)(SEQ ID NOs. 7), enhancer e HGT_128h (eAi119.0) (SEQ ID NO: 8), Enhancer eHGT_140h (eAi120.0) (SEQ ID NO: 9), Enhancer eHGT_023h (eAi104.0) (SEQ ID NO: 10), Enhancer eHGT_359h (SEQ ID NO: 11), Enhancer eHGT_019h (eAi101.0) (SEQ ID NO: 12), Enhancer eHGT_064h (eAi110.0) (SEQ ID NO: 13), Enhancer eHGT_022h (eAi103.0) (SEQ ID NO: 14), Enhancer eHGT_022m (eAi102.0) (SEQ ID NO: 15), Enhancer eHGT_017h (eAi100.0) (SEQ ID NO: 16), Enhancer eHGT_017m (SEQ ID NO: 17), hsA2 (SEQ ID NO: 18), β-globin minimal promoter (pBGmin / minBGlobin / minBGprom) (SEQ ID NO: 19), minCMV promoter (SEQ ID NO: 20), Mutant minCMV promoter (SacI RE site removal) (SEQ ID NO: 21), minRho promoter (SEQ ID NO: 22), minRho* promoter (SEQ ID NO: 23), Hsp68 minimal promoter (proHSP68) (SEQ ID NO: 24), SYFP2 (SEQ ID NO: 25), EGFP (SEQ ID NO: 26), Optimized Flp recombinase (FlpO) (SEQ ID NO: 27), Improved Cre recombinase (iCre) (SEQ ID NO: 28), SP10 insulator (SP10ins) (SEQ ID NO: 29), 3xSP10ins (SEQ ID NO: 30), W PRE3 (SEQ ID NO: 31), BGHpA (SEQ ID NO: 32), P2A (SEQ ID NO: 33), T2A (SEQ ID NO: 34), E2A (SEQ ID NO: 35), F2A (SEQ ID NO: 36), Exemplary Plasmid Backbone 1 - Left ITR (SEQ ID NO: 124), Exemplary Plasmid Backbone 1 - Right ITR (SEQ ID NO: 125), Exemplary Plasmid Backbone 2 - Left ITR (SEQ ID NO: 126), Exemplary Plasmid Backbone 2 - Right ITR (SEQ ID NO: 127), PHP.eB Capsid (SEQ ID NO: 37), AAV9 VP1 capsid protein (SEQ ID NO: 38), tTA2 (SEQ ID NO: 39), plasmid backbone 1 (SEQ ID NO: 40), plasmid backbone 2 (SEQ ID NO: 41), AiP1146 (T502-047, vAi30.0) (SEQ ID NO: 43), AiP1113 (T502-053, vAi30.1) (SEQ ID NO: 44), AiP1147 (T502-048, vAi31.0) (SEQ ID NO: 45), AiP989 (TG989) vAi11.0,) (SEQ ID NO: 46), AiP1013(TG1013, vAi12.0) (SEQ ID NO: 47), AiP1012(TG1012, vAi14.0) (SEQ ID NO: 48), CN1525(vAi115.0) (SEQ ID NO: 49), CN1528(vAi116.0) (SEQ ID NO: 50), CN1532(vAi117.0) (SEQ ID NO: 51), CN1621(vAi119.0) (SEQ ID NO: 52), CN1633(vAi120.0) (SEQ ID NO: 53), CN1259(vAi104.0) (SEQ ID NO: 54), CN2045 (SEQ ID NO: 55), CN1255 (vAi101.0) (SEQ ID NO: 56), CN1408 (vAi110.0) (SEQ ID NO: 57), CN1258 (vAi103.0) (SEQ ID NO: 58), CN1279 (vAi102.0) (SEQ ID NO: 59), CN1253 (vAi100.0) (SEQ ID NO: 60), CN1274 (SEQ ID NO: 61), Lactase (SEQ ID NO: 62), Lipase (SEQ ID NO: 63), Helicase (SEQ ID NO: 64), Amylase (SEQ ID NO: 65), α-Glucosidase (SEQ ID NO: 66), Transcription factor SP1 (SEQ ID NO: 67), Transcription factor AP-1 (SEQ ID NO: 68), Heat shock factor protein 1 (SEQ ID NO: 69), CCAAT / enhancer-binding protein (C / EBP) β isoform a (SEQ ID NO: 69) 70), 44105 (SEQ ID NO: 71), Transforming Growth Factor Receptor β1 (SEQ ID NO: 72), Platelet-Derived Growth Factor Receptor (SEQ ID NO: 73), Epidermal Growth Factor Receptor (SEQ ID NO: 74), Vascular Endothelial Growth Factor Receptor (SEQ ID NO: 75), Interleukin-8 Receptor α (SEQ ID NO: 76), Caveolin (SEQ ID NO: 77), Dynamin (SEQ ID NO: 78), Clathrin Heavy Chain 1 Isoform 1 (SEQ ID NO: 79), Clathrin Heavy Chain 2 Isoform 1 (SEQ ID NO: 80), Clathrin Light Chain A Isoform a (SEQ ID NO: 81), Clathrin Light Chain B Isoform a (SEQ ID NO: 82), Ras-Related Protein Rab-4A Isoform 1 (SEQ ID NO: 83), Ras-Related Protein Rab-11A, UniProtKB / Swiss-Prot:P62491.3: (SEQ ID NO: 84), Platelet-derived growth factor (SEQ ID NO: 85), Transforming growth factor-β3 (SEQ ID NO: 86), Nerve growth factor (SEQ ID NO: 87), Epidermal growth factor (EGF) (SEQ ID NO: 88), GTPase HRas (SEQ ID NO: 89), Cocaine and amphetamine regulatory transcript (chain A) (SEQ ID NO: 90), Protachykinin-1 (SEQ ID NO: 91), Protachykinin-1 (SEQ ID NO: 92), Oxytocin-neurophysin-1 (SEQ ID NO: 93), Oxytocin at positions 20-28 of Oxytocin-neurophysin-1 (SEQ ID NO: 94), Somatostatin (SEQ ID NO: 95), Myosin light chain kinase, Green fluorescent protein, Calmodulin chimera (chain A) (SEQ ID NO: 96), Genetically encoded green calcium indicator NTnC (chain A) (SEQ ID NO: 97), Calcium indicator TN-XXL (SEQ ID NO: 98), BRET-based autoluminescent calcium These include indicators (SEQ ID NO: 99), calcium indicator protein OeNL(Ca2+)-18u (SEQ ID NO: 100), GCaMP6m (SEQ ID NO: 101), GCaMP6s (SEQ ID NO: 102), GCaMP6f (SEQ ID NO: 103), channellopsin-1 (SEQ ID NOs: 104 and 105), channelrhodopsin-2 (SEQ ID NOs: 106 and 107), CRISPR-related protein (Cas) (SEQ ID NO: 108), Cas9 (SEQ ID NO: 109), CRISPR-related endonuclease Cpf1 (SEQ ID NO: 110), ribonuclease-4 (SEQ ID NO: 111), deoxyribonuclease IIβ (SEQ ID NO: 112), sodium channel protein type 1 subunit α (SEQ ID NO: 113), potassium voltage-gated channel subfamily KQT member 2 (SEQ ID NO: 114), and voltage-gated L-type calcium channel subunit α-1C (SEQ ID NO: 115). [Modes for carrying out the invention]

[0011] To fully understand the biology of the brain, it is necessary to distinguish and define various cell types, and to further study them, it is necessary to identify artificial expression constructs that can selectively label and disrupt them. Tasic, Curr. Opin. Neurobiol. 50, 242-249 (2018), Zeng & Sanes, Nat. Rev. Neurosci. 18, 530-546 (2017). In mice, recombinase driver lines have been used to prove highly effective in labeling cell populations that share marker gene expression. Daigle et al., Cell 174, 465-480. e22 (2018), Taniguchi et al., Neuron 71, 995-1013 (2011), Gong et al., J. Neurosci. 27, 9817-9823 (2007). However, creating, maintaining, and using strains that label cell types with high specificity can be costly and frequently require triple transgenic crosses, which result in a low number of experimental animals. Furthermore, these tools require germline transgenic animals and are therefore not applicable to humans.

[0012] This disclosure provides artificial expression constructs that selectively drive gene expression in target central nervous system cell populations. Target central nervous system cell populations include gamma-aminobutyric acid (GABA) ergic neurons in general, and / or GABAergic neuron cell types such as lysosomal membrane protein 5 (Lamp5) neurons, vasoactive intestinal polypeptide (Vip) neurons, somatostatin (Sst) neurons, and parvalbumin (Pvalb) neuron cell types. Telencephalon (IT) neurons in layer 4 (L4) and / or layer 5 (L5), deep cerebellar nucleus neurons, or cerebellar Purkinje cells can also be targeted for selective gene expression.

[0013] A specific embodiment of the artificial expression construct utilizes the following enhancers to selectively drive gene expression within a target central nervous system cell population as follows (enhancer / target cell population): Grik1_enhGad2-1 / GABAergic neurons in general, Grik1_enhGad2-2 / GABAergic neurons in general, mscRE5 / GABAergic neurons in general, mscRE8 / GABAergic neurons in general, eHGT_019h / Lamp5 neurons, eHGT_022h / Lamp5 and Vip neurons, eHGT_022m / Lamp5 and Vip Neurons, eHGT_017h / Lamp5, Vip and Sst neurons, eHGT_17m / Lamp5, Vip and Sst neurons, eHGT_079h / parvalbumin (Pvalb) neuron cell type, eHGT_082h / Pvalb neuron cell type and deep cerebellar nuclei cells, eHGT_086h / Pvalb neuron cell type, eHGT_128h / Pvalb neuron cell type, eHGT_140h / Pvalb neuron cell type, eHGT_064h / Pvalb and Sst neuron cell type, eHGT_023h / Pvalb cell type, L4 and L5 IT neurons, cerebellar Purkinje cells, and eHGT_359 / Pvalb cell type and cerebellar Purkinje cells. In certain embodiments, unless otherwise specified, the target cell type is neocortical cell type.

[0014] Certain embodiments provide an artificial expression construct that includes the characteristics of the vectors described herein, including vectors: AiP1146, AiP1113, AiP1147, AiP1147, AiP1013, AiP1012, CN1525, CN1528, CN1532, CN1621, CN1633, CN1259, CN2045, CN1255, CN1408, CN1258, CN1279, CN1253, and CN1274.

[0015] Herein, aspects of the present disclosure will be described using the following additional options and details: (i) artificial expression constructs and vectors for selective expression of genes in selected cell types; (ii) compositions for administration; (iii) cell lines comprising the artificial expression constructs; (iv) transgenic animals; (v) methods of use; (vi) kits and commercial packaging; (vii) exemplary embodiments; (viii) experimental examples; and (ix) the final paragraph.

[0016] (i) Artificial expression constructs and vectors for selective expression of genes in selected cell types. An artificial expression construct disclosed herein comprises (i) an enhancer sequence resulting in selective expression of a coding sequence within a target central nervous system cell type, (ii) the coding sequence to be expressed, and (iii) a promoter. The artificial expression construct may also include other regulatory elements if necessary or beneficial.

[0017] In certain embodiments, an “enhancer” or “enhancer element” is a cis-acting sequence that increases the transcription level associated with the promoter and can function in either orientation relative to the promoter and the transcribed coding sequence, and can be located upstream or downstream of the promoter or the transcribed coding sequence. There are art-recognized methods and techniques for measuring the function of enhancer element sequences. Specific examples of enhancer sequences used in the artificial expression constructs disclosed herein include Grik1_enhGad2-1, Grik1_enhGad2-2, mscRE5, mscRE8, eHGT_019h, eHGT_022h, eHGT_022m, eHGT_017h, eHGT_17m, eHGT_079h, eHGT_082h, eHGT_086h, eHGT_128h, eHGT_140h, eHGT_064h, eHGT_023h, and eHGT_359.

[0018] In certain embodiments, the target central nervous system cell type enhancer is an enhancer that is uniquely or primarily utilized by the target central nervous system cell type. The target central nervous system cell type enhancer enhances gene expression in the target central nervous system cell type but does not substantially direct gene expression in other non-target cell types, and therefore has neuronal-specific transcriptional activity.

[0019] If a coding sequence is selectively expressed in selected cells and substantially not expressed in other cell types, the product of the coding sequence is preferentially expressed in the selected cell type. In certain embodiments, preferential expression is greater than 50% expression compared to a reference cell type, greater than 60% expression compared to a reference cell type, greater than 70% expression compared to a reference cell type, greater than 80% expression compared to a reference cell type, or greater than 90% expression compared to a reference cell type. In certain embodiments, the reference cell type refers to non-target cells. Non-target cells may be located within the same anatomical structure as the target cells and / or protrude into a common anatomical region. In certain embodiments, the reference cell type is located within an anatomical structure adjacent to the anatomical structure containing the target cell type. In certain embodiments, the reference cell type is a non-target GABAergic cell having a different gene expression profile than the target cells.

[0020] In certain embodiments, the coding sequence product may be expressed at low levels in unselected cell types, for example, at less than 1% or 1%, 2%, 3%, 5%, 10%, 15%, or 20% of the level at which the product is expressed in selected cells. In certain embodiments, the target central nervous system cell type is the only cell type that expresses the correct combination of transcription factors that bind to the enhancers disclosed herein to drive gene expression. Therefore, in certain embodiments, expression occurs only within the target cell type.

[0021] In certain embodiments, target cell types (e.g., nerves, neurons, and / or non-neurons) can be identified based on transcriptional profiles as described in Tasic et al., Nature 563, 72-78 (2018) and Hodge et al., Nature 573, 61-68 (2019). For reference, the following descriptions of neuronal cell types and their distinctive features are also provided.

[0022] Neocortic GABAergic subclass: • All: Expresses the GABA synthesis genes Gad1 / GAD1 and Gad2 / GAD2.

[0023] Lamp5, Sncg, Serpinf1, and Vip: Developmentally originate from neuronal progenitor cells of the caudal ganglion eminence (CGE) or preoptic area (POA).

[0024] • Sst and Pvalb: Developmentally derived from neuronal progenitor cells of the medial basal ganglia primordium (MGE).

[0025] • Lamp 5: Found in many neocortical layers, especially the upper part (L1-L2 / 3), and mainly exhibits neuroglial and single-bouquet morphologies.

[0026] • Sncg: Found in many neocortical layers, it has molecular overlap with Lamp5 and Vip cells, but Lamp5 or Vip expression is inconsistent, while Sncg expression is more consistent.

[0027] • Serpinf1: Found in many neocortical layers, it has molecular overlap with Sncg and Vip cells, but Sncg or Vip expression is inconsistent, while Serpinf1 expression is more consistent.

[0028] • Vip: Found in many neocortical layers, but especially frequently in the upper layers (L1-L4), and highly expresses the neurotransmitter vasoactive intestinal peptide (Vip).

[0029] • Sst: Found in many neocortical layers, but particularly frequently in the lower layers (L5-L6). They highly express the neurotransmitter somatostatin (Sst) and frequently block dendritic input to postsynaptic neurons. This subclass includes sleep-active Sst Chodl neurons (also expressing Nos1 and Tacr1) that are quite different from other Sst neurons but express several co-marker genes including Sst. In humans, SST gene expression is often detected in Lamp5+ cells in layer 1.

[0030] • Pvalb: Found in many neocortical layers, but especially frequently in the lower layers (L5-L6). They highly express the calcium-binding protein parvalbumin (Pvalb), express the neuropeptide Tac1, and frequently suppress postsynaptic neuronal output. Most fast-spiking GABAergic cells strongly express Pvalb. This subclass includes chandelier cells, which have a distinct chandelier-like morphology and express the markers Cpne5 and Vipr2 in mice, and NOG and UNC5B in humans.

[0031] • Meis2: A distinct subclass defined by a single type that expresses only the Meis2 gene and does not express several other genes expressed by all other neocortical GABAergic types (e.g., Thy1 and Scn2b). This type is found in L6b and subcortical white matter.

[0032] Neocortic glutamatergic subclass: • All: Express glutamate signaling molecules Slc17a6 and / or Slc17a7. They all express Snap25, lack Gad1 / Gad2 expression, and lack Slc1A3 expression.

[0033] • L2 / 3 IT: Primarily located in layers 2 and 3, and mainly has telencephalon (intercortical) projections.

[0034] • L4 IT: Primarily located in layer 4, it mainly has focal or telencephalon (intercortical) projections.

[0035] • L5 IT: Primarily located in layer 5, it mainly has telencephalon (corticocortical) projections. Also known as L5a.

[0036] • L5 PT: Primarily located in layer 5, these cells mainly have subcortical (pyramidal or cortical efferent) projections. They are also called L5b, L5 CF (cortical efferent), or L5 ET (extratelncenal). This subclass includes cells located in the primary motor cortex and adjacent regions that are corticospinal projection neurons, which are associated with motor neuron / motor diseases such as ALS. This subclass includes thick, tufted pyramidal neurons, which include specific cell types found only in specialized regions, such as Betz cells, Meynert cells, and von Economo cells.

[0037] • L5 NP: Primarily located in layer 5, and mainly has projections nearby.

[0038] • L6 CT: Primarily located in layer 6, and mainly has corticothalamic projections.

[0039] • L6 IT: Primarily located in layer 6, these cells mainly have telencephalon (intercortical) projections. This subclass includes L6 IT Car3 cells, which are very similar to the intracortical projection cells of the claustrum.

[0040] L6b: Primarily located in the neocortical subplate (L6b), it has local (near-cell body) projections, several intercortical projections from VISp to the anterior cingulate cortex, and subcortical projections to the thalamus.

[0041] Cajal Retius cells, a distinct subclass defined by a single type of CR:L1, express distinct molecular markers Lhx5 and Trp73.

[0042] Cerebellar Purkinje cells: These are the only projection neurons and large GABAergic neurons that are the sole output from the cerebellum. Their cell bodies form a monolayer, the so-called "Purkinje cell layer," and they express parvalbumin.

[0043] Deep cerebellar nucleus neurons: Neurons located within the deep cerebellar nucleus structure. These include excitatory cells and GABAergic cells that express the gene Pvalb.

[0044] Non-neuronal subclass: • Astrocytes: Neuroectoderm-derived glial cells that express the marker Aqp4 and often GFAP, but do not express the neuronal marker SNAP25. They can have a distinct star-shaped morphology and are involved in supporting the metabolism of other cells in the brain. Multiple astrocyte morphologies have been observed in mice and humans.

[0045] • Oligodendrocytes: Neuroectoderm-derived glial cells that express the marker Sox10. This category includes oligodendrocyte progenitor cells (OPCs). Oligodendrocytes are a subclass primarily involved in neuronal myelin formation.

[0046] • VLMCs: Vascular leptomeningeal cells (VLMCs) are part of the meninges that surround the outer layer of the cortex and express the marker genes Lum and Col1a1.

[0047] • Pericytes: Vascular-related cells that express the marker genes Kcnj8 and Abcc9. Pericytes surround endothelial cells and are important for regulating capillary blood flow, and are involved in blood-brain barrier permeability.

[0048] SMC: A type of vascular-related smooth muscle cell that expresses the marker gene Acta2. SMCs cover the arterioles of the brain and are involved in blood-brain barrier permeability.

[0049] • Endothelial cells: Cells that line the blood vessels of the brain. Endothelial cells express the markers Tek and PDGF-B.

[0050] Microglia: Hematopoietic-derived immune cells that are macrophages normally residing in the brain. They are perivascular macrophages (PVMs) that may be temporarily associated with brain tissue or included as a byproduct of brain dissection. Microglia are known to express Cx3cr1, Tmem119, and PTPRC (CD45).

[0051] In certain embodiments, the coding sequence is a heterogeneous coding sequence that codes for an effector element. An effector element is a sequence that is expressed to achieve a intended effect and actually achieves that intended effect. Examples of effector elements include reporter genes / proteins and functional genes / proteins.

[0052] Examples of reporter genes / proteins include those expressed by Addgene ID#83894(pAAV-hDlx-Flex-dTomato-Fishell_7), 83895(pAAV-hDlx-Flex-GFP-Fishell_6), 83896(pAAV-hDlx-GiDREADD-dTomato-Fishell-5), 83898(pAAV-mDlx-ChR2-mCherry-Fishell-3), 83899(pAAV-mDlx-GCaMP6f-Fishell-2), 83900(pAAV-mDlx-GFP-Fishell-1), and 89897(pcDNA3-FLAG-mTET2(N500)).Exemplary reporter genes include, in particular, blue fluorescent proteins (e.g., eBFP, eBFP2, Azurite, mKalama1, GFPuv, Sapphire, T-sapphire), cyan fluorescent proteins (e.g., eCFP, Cerulean, CyPet, AmCyanl, Midoriishi-Cyan, mTurquoise), green fluorescent proteins (e.g., GFP, GFP-2, tagGFP, turboGFP, EGFP, Emerald, Azami Green, Monomeric Azami Green (mAzamigreen), CopGFP, AceGFP, avGFP, ZsGreenl, Oregon Green (Trademark) (Thermo Fisher Scientific)), luciferase, and orange fluorescent proteins (mOrange, mKO, Kusabira-Orange, Monomeric). Examples include Kusabira-Orange, mTangerine, tdTomato, dTomato), red fluorescent proteins (mKate, mKate2, mPlum, DsRed monomer, mCherry, mRuby, mRFP1, DsRed-Express, DsRed2, DsRed-Monomer, HcRed-Tandem, HcRedl, AsRed2, eqFP611, mRaspberry, mStrawberry, Jred, Texas Red (trademark) (Thermo Fisher Scientific Inc.)), far-red fluorescent proteins (e.g., mPlum and mNeptune), yellow fluorescent proteins (e.g., YFP, eYFP, Citrine, SYFP2, Venus, YPet, PhiYFP, ZsYellowl), and tandem conjugates.

[0053] GFP is composed of 238 amino acids (26.9 kDa) and was originally isolated from the jellyfish Aequorea victoria / Aequorea aequorea / Aequorea forskalea, which emit green fluorescence when exposed to blue light. GFP from A. victoria has a major excitation peak at 395 nm and a minor excitation peak at 475 nm. Its emission peak is at 509 nm, which is in the low-wavelength green portion of the visible spectrum. GFP from the sea slug (Renilla reniformis) has a single major excitation peak at 498 nm. Due to its potential for widespread use and the evolving needs of researchers, many different variants of GFP have been genetically engineered. The first major improvement was a single-point mutation (S65T) reported by Roger Tsien in Nature in 1995. This mutation dramatically improved the spectral properties of GFP, resulting in increased fluorescence, photostability, and a shift of the major excitation peak to 488 nm while maintaining the peak emission at 509 nm. By adding a 37°C folding efficiency (F64L) point mutant to this scaffold, highly sensitive GFP (EGFP) was produced. EGFP is also known by its optical cross-section of 9.13 x 10⁻²¹ m². 2 It has a molecular extinction coefficient (denoted by ε), which is also cited as 55,000 L / (mol·cm). A series of mutations that enable superfolder GFP, i.e., GFP to rapidly fold and mature even when fused to peptides that are not fully folded, were reported in 2006.

[0054] Yellow fluorescent protein (YFP) is a genetic variant of green fluorescent protein derived from Aequorea victoria. Its excitation peak is at 514 nm and its emission peak is at 527 nm.

[0055] Examples of functional molecules include functional ion transporters, cell transport proteins, enzymes, transcription factors, neurotransmitters, calcium reporters, channelrhodopsins, guide RNAs, nucleases, or designer receptors (DREADDs) that are exclusively activated by designer drugs.

[0056] Ion transporters are transmembrane proteins that mediate the transport of ions across the cell membrane. These transporters are widely present across most cell types and are crucial for regulating cellular excitability and homeostasis. Ion transporters are involved in numerous cellular processes, including action potentials, synaptic transmission, hormone secretion, and muscle contraction. Many important biological processes in living cells involve the transport of calcium (Ca) through such ion channels. 2+ ), potassium (K + ) and sodium (Na + This involves the movement of cations such as ions. In certain embodiments, the ion transporter includes voltage-gated sodium channels (e.g., SCN1A), potassium channels (e.g., KCNQ2), and calcium channels (e.g., CACNA1C).

[0057] Examples of enzymes, transcription factors, receptors, membrane proteins, cell transport proteins, signaling molecules, and neurotransmitters include enzymes such as lactase, lipase, helicase, α-glucosidase, and amylase; transcription factors such as SP1, AP-1, heat shock factor protein 1, C / EBP (CCAA-T / enhancer-binding protein), and Oct-1; receptors such as transforming growth factor receptor β1, platelet-derived growth factor receptor, epidermal growth factor receptor, vascular endothelial growth factor receptor, and interleukin-8 receptor α; membrane proteins; cell transport proteins such as clathrin, dynamin, caveolin, Rab-4A, and Rab-11A; signaling molecules such as nerve growth factor (NGF), platelet-derived growth factor (PDGF), transforming growth factor β (TGFβ), epidermal growth factor (EGF), GTPases, and HRas; and neurotransmitters such as cocaine and amphetamine-regulated transcripts, substance P, oxytocin, and somatostatin.

[0058] In certain embodiments, functional molecules include reporters of neuronal function and state, such as calcium reporters. Intracellular calcium concentration is an important predictor of numerous cellular activities, including neuronal activation, myocyte contraction, and second messenger signaling. A highly sensitive and convenient technique for monitoring intracellular calcium levels is the use of genetically encoded calcium indicators (GECIs). Among GECIs, green fluorescent protein (GFP)-based calcium sensors called GCaMPs are efficient and widely used tools. GCaMPs are formed by the fusion of M13 and calmodulin proteins to the N-terminus and C-terminus of a circulatingly substituted GFP. Several GCaMPs produce different fluorescence emission spectra (Zhao et al., Science, 2011, 333(6051):1888-1891). Examples of GECIs exhibiting green fluorescence include GCaMP3, GCaMP5G, GCaMP6s, GCaMP6m, GCaMP6f, jGCaMP7s, jGCaMP7c, jGCaMP7b, and jGCaMP7f. Furthermore, examples of GECIs exhibiting red fluorescence include jRGECO1a and jRGECO1b. AAV products containing GECIs are commercially available.For example, Vigene Biosciences offers AAV8-CAG-GCaMP3 (catalog number: BS4-CX3AAV8), AAV8-Syn-FLEX-GCaMP6s-WPRE (catalog number: BS1-NXSAAV8), AAV8-Syn-FLEX-GCaMP6s-WPRE (catalog number: BS1-NXSAAV8), AAV9-CAG-FLEX-GCaMP6m-WPRE (catalog number: BS2-CXMAAV9), AAV9-Syn-FLEX-jGCaMP7s-WPRE (catalog number: BS12-NXSAAV9), and AAV9-CAG-FLEX We offer AAV products including -jGCaMP7f-WPRE (catalog number: BS12-CXFAAV9), AAV9-Syn-FLEX-jGCaMP7b-WPRE (catalog number: BS12-NXBAAV9), AAV9-Syn-FLEX-jGCaMP7c-WPRE (catalog number: BS12-NXCAAV9), AAV9-Syn-FLEX-NES-jRGECO1a-WPRE (catalog number: BS8-NXAAAV9), and AAV8-Syn-FLEX-NES-jRCaMP1b-WPRE (catalog number: BS7-NXBAAV8).

[0059] In certain embodiments, the calcium reporter comprises a genetically encoded calcium indicator GECI, NTnC; myosin light chain kinase, GFP, calmodulin chimera; calcium indicator TN-XXL; BRET-based autoluminescent calcium indicator; and / or calcium indicator protein OeNL(Ca2+)-18u).

[0060] In certain embodiments, the functional molecule includes a modulator of neuronal activity, such as channelrhodopsins (e.g., channelrhodopsin-1, channelrhodopsin-2, and their variants). Channelrhodopsins are a subfamily of retinilidene proteins (rhodopsins) that function as light-driven ion channels. In addition to channelrhodopsin-1 (ChR1) and channelrhodopsin-2 (ChR2), several variants of channelrhodopsins have been developed. For example, Lin et al. (Biophys J, 2009, 96(5):1803-14) describe the creation of chimeras of the transmembrane domains of ChR1 and ChR2 in combination with site-directed mutagenesis. Zhang et al. (Nat Neurosci, 2008, 11(6):631-3) describe VChR1, a red-shifted channelrhodopsin variant. Other known channelrhodopsin variants include ChR2 (Nagel, et al., Proc Natl Acad Sci USA, 2003, 100(24):13940-5), ChR2 / H134R (Nagel, G., et al., Curr Biol, 2005, 15(24):2279-84), and ChD / ChEF / ChIEF (Lin, JY, et al., Biophys J, 2009, 96(5):1803-14), which are activated by blue light (470 nm) but are not sensitive to orange / red light. Further variants are described in Lin, Experimental Physiology, 2010, 96.1:19-25 and Knopfel et al., The Journal of Neuroscience, 2010, 30(45):14998-15004.

[0061] In certain embodiments, the functional molecule may include DNA and RNA editing tools such as CRISPR / CAS (e.g., guide RNA and nucleases such as Cas, Cas9, or cpf1). The functional molecule may also include genetically modified Cpf1, a single gRNA (see, for example, Jinek et al. (2012) Science 337:816-821, Jinek et al. (2013) eLife2:e00471, Segal (2013) eLife2:e00563), or an editase, guide RNA molecule, or homologous recombination donor cassette, as described in US2018 / 0030425, US2016 / 0208243, WO / 2017 / 184768, and Zetsche et al. (2015) Cell 163:759-771) or an editase, guide RNA molecule, or homologous recombination donor cassette.

[0062] Further effector elements include Cre, iCre, dgCre, FlpO, and tTA2. iCre refers to Cre with modified codons. dgCre refers to a highly sensitive GFP / Cre recombinase fusion gene with an N-terminal fusion of the first 159 amino acids of the chromosomal dihydrofolate reductase gene (DHFR or folA) of the Escherichia coli K-12 strain, modified to include the G67S mutation and also the R12Y / Y100I destabilization domain mutation. FlpO refers to a codon-optimized form of FLPe that significantly increases protein expression and FRT recombination efficiency in mouse cells. Similar to the Cre / LoxP system, the FLP / FRT system is widely used for gene expression (and the creation of conditional knockout mice mediated by the FLP / FRT system). tTA2 refers to tetracycline transactivator.

[0063] Exemplary expressible elements are expression products that do not contain effector elements, such as non-functional or defective proteins. In certain embodiments, expressible elements can provide a method for studying the effects of their functional counterparts. In certain embodiments, expressible elements are non-functional or defective based on mutations that have been genetically engineered to render them non-functional. In these embodiments, the non-expressible elements are as structurally similar as possible to their functional counterparts.

[0064] Exemplary self-cleaving peptides include 2A peptides, which result in the production of two proteins from a single mRNA molecule. 2A sequences are short (e.g., 20 amino acids), allowing for greater use in size-constrained constructs. Specific examples include P2A, T2A, E2A, and F2A. In certain embodiments, the artificial expression construct includes an internal ribosome entry site (IRES) sequence. The IRES allows the ribosome to initiate translation at a second internal site of the mRNA molecule, resulting in the production of two proteins from a single mRNA molecule.

[0065] The coding sequences that encode molecules (e.g., RNA, proteins) described herein can be obtained from publicly available databases and publications. The coding sequences may further include various sequence polymorphisms, mutations, and / or sequence variants, such changes that do not affect the function of the encoded molecule. The terms “encode” or “encoding” refer to the properties of nucleic acid sequences, such as vectors, plasmids, genes, cDNA, and mRNA, that serve as templates for the synthesis of other molecules, such as proteins.

[0066] The term “gene” may include not only coding sequences but also regulatory regions such as promoters, enhancers, and insulators, and / or post-regulatory elements such as termination regions. The term may further include all introns and other DNA sequences spliced ​​from mRNA transcripts, along with variants arising from alternative splicing sites. Sequences may also include reference sequences or degenerate codons of sequences that may be introduced to provide codon selection in a particular organism or cell type.

[0067] Promoters may include general promoters, tissue-specific promoters, cell-specific promoters, and / or cytoplasm-specific promoters. Promoters may also include strong promoters, weak promoters, constitutive expression promoters, and / or inducible promoters. Inducible promoters induce expression in response to specific conditions, signals, or cellular events. For example, a promoter may be an inducible promoter that requires a specific ligand, small molecule, transcription factor, or hormonal protein to transcribe from it. Specific examples of promoters include minBglobin, CMV, minCMV, and mutant minCMV. * (minCMV * (minCMV is minCMV with the SacI restriction site removed), minRho, minRho * (minRho * Examples include the minRho promoter (with the SacI restriction site removed), the SV40 immediate-type promoter, the Hsp68 minimal promoter (proHSP68), and the Roussarcoma virus (RSV) long-terminal repeat (LTR) promoter. Minimal promoters do not have the activity to drive gene expression on their own, but can be activated to drive gene expression when ligated to a proximal enhancer element.

[0068] In certain embodiments, the expression construct is provided within a vector. The term vector refers to a nucleic acid molecule that can import or transport another nucleic acid molecule, such as an expression construct. The imported nucleic acid is generally ligated, for example, inserted, into the vector nucleic acid molecule. The vector may contain sequences that direct autonomous replication within a cell, or sequences that enable integration into host cell DNA. Useful vectors include, for example, plasmids (e.g., DNA plasmids or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors.

[0069] The term "viral vector" is widely used to refer to nucleic acid molecules containing viral component elements that facilitate the transfer and expression of non-native nucleic acid molecules within cells. The term "adeno-associated virus vector" refers to viral vectors or plasmids containing structural and functional genetic elements, or parts thereof, primarily derived from AAV. The term "retroviral vector" refers to viral vectors or plasmids containing structural and functional genetic elements, or parts thereof, primarily derived from retroviruses. The term "lentiviral vector" refers to viral vectors or plasmids containing structural and functional genetic elements, or parts thereof, primarily derived from lentiviruses, etc. The term "hybrid vector" refers to vectors containing structural and / or functional genetic elements derived from multiple viral types.

[0070] An adenovirus vector refers to a construct that (a) supports the packaging of an expression construct and (b) contains sufficient adenovirus sequences to express the coding sequence cloned therein in sense or antisense direction. Recombinant adenovirus vectors contain a genetically modified form of adenovirus. Knowledge of the genetic makeup of adenoviruses, which are 36kb linear double-stranded DNA viruses, allows for the substitution of large fragments of adenovirus DNA with foreign sequences of up to 7kb. In contrast to retroviruses, adenovirus DNA can replicate in an episomal manner without the potential for genotoxicity, so adenovirus infection of host cells does not result in integration into chromosomes. Adenoviruses are also structurally stable, and no genomic rearrangements have been detected after large-scale amplification.

[0071] Adenoviruses are particularly well-suited for use as gene transfer vectors due to their medium-sized genome, ease of manipulation, high titer, broad range of target cells, and high infectivity. The viral genome contains 100-200 base pair reverse repeats (ITRs) at both ends, which are cis-elements necessary for viral DNA replication and packaging. The early (E) and late (L) regions of the genome contain different transcription units that are separated by the initiation of viral DNA replication. The E1 region (E1A and E1B) encodes proteins involved in regulating the transcription of the viral genome and several cellular genes. Expression of the E2 region (E2A and E2B) results in the synthesis of proteins for viral DNA replication. These proteins are involved in DNA replication, late gene expression, and host cell shut-off. The products of late genes, including most of the viral capsid proteins, are expressed only after critical processing of a single primary transcript generated by the major late promoter (MLP). MLP is particularly efficient in the later stages of infection, and all mRNA generated from this promoter has a 5'-tripertite leader (TPL) sequence, making it a favorable promoter for translation.

[0072] Aside from the requirement that the adenovirus vector is replication-deficient or at least conditionally defective, the properties of the adenovirus vector are not considered important for the successful implementation of the particular embodiments disclosed herein. The adenovirus may be any of the 42 different known serotypes or subgroups A-F. In certain embodiments, adenovirus type 5 of subgroup C is a preferred starting material for obtaining a conditionally replication-deficient adenovirus vector for use in those embodiments, because adenovirus type 5 is a human adenovirus for which much biochemical and genetic information is known and has historically been used in most constructs that use adenovirus as a vector.

[0073] As shown, a typical vector is a replication defect and lacks the adenovirus E1 region. Therefore, the simplest approach would be to introduce a polynucleotide encoding the gene of interest at the location where the E1 coding sequence has been removed. However, the insertion site of the construct within the adenovirus sequence is not critical. The polynucleotide encoding the gene of interest can also be inserted in place of the deleted E3 region in the E3 substitution vector, or in the E4 region where a helper cell line or helper virus complements the E4 deficiency.

[0074] Adeno-associated virus (AAV) is a parvovirus discovered as a contaminant in adenovirus stocks. It is a ubiquitous virus not associated with any disease (antibodies are present in 85% of the US human population). It is also classified as a dependent virus because its replication depends on the presence of helper viruses such as adenoviruses. Various serotypes have been isolated, of which AAV-2 is the best characterized. AAV has single-stranded linear DNA capsidated to capsid proteins VP1, VP2, and VP3 to form icosahedral virions with a diameter of 20–24 nm.

[0075] The AAV DNA is 4.7 kilobases long. It contains two open reading frames, flanked by two ITRs. The AAV genome contains two major genes, rep and cap. The rep gene codes for proteins involved in viral replication, while cap codes for capsid proteins VP1-3. Each ITR forms a T-shaped hairpin structure. These terminal repeats are the only cis-components of AAV essential for chromosomal integration. Therefore, AAV can be used as a vector with all viral coding sequences removed and replaced by a cassette of delivery genes. Three AAV viral promoters have been identified and named p5, p19, and p40 according to their mapped locations. Transcription from p5 and p19 results in the production of rep proteins, while transcription from p40 produces capsid proteins.

[0076] AAVs stand out for use in this disclosure due to their superior safety profile and the fact that their capsids and genomes can be modified to enable expression in selected cell populations. scAAV refers to self-complementary AAV. pAAV refers to plasmid adeno-associated viruses. rAAV refers to recombinant adeno-associated viruses.

[0077] Other viral vectors can also be used. For example, vectors derived from viruses such as vaccinia virus, poliovirus, and herpesvirus can be used. They offer several attractive properties to various mammalian cells.

[0078] Retroviruses are a common tool for gene delivery. A "retrovirus" is an RNA virus that reverse transcribes its genomic RNA into a linear double-stranded DNA copy and then covalently integrates that genomic DNA into the host genome. Once integrated into the host genome, the virus is called a "provirus." The provirus functions as a template for RNA polymerase II, directing the expression of RNA molecules that encode structural proteins and enzymes necessary to produce new viral particles.

[0079] Exemplary retroviruses suitable for use in specific embodiments include Moloney's mouse leukemia virus (M-MuLV), Moloney's mouse sarcoma virus (MoMSV), Harvey's mouse sarcoma virus (HaMuSV), mouse mammary cancer virus (MuMTV), gibbon leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, friend mouse leukemia virus, mouse stem cell virus (MSCV), Rous sarcoma virus (RSV), and lentivirus.

[0080] "Lentivirus" refers to a group (or genus) of compound retroviruses. Exemplary lentiviruses include HIV (human immunodeficiency virus, including HIV1 and HIV2), Visna Maedivirus (VMV), canine arthritis encephalitis virus (CAEV), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV), and simian immunodeficiency virus (SIV). In certain embodiments, an HIV-based vector backbone (i.e., an HIV cis-acting sequence element) may be used.

[0081] Enhanced safety for the use of some vectors can be provided by replacing the U3 region of the 5'LTR with a heterologous promoter to drive transcription of the viral genome during viral particle production. Examples of heterologous promoters that can be used for this purpose include, for example, the promoters for viral Simian virus 40 (SV40) (e.g., early or late), cytomegalovirus (CMV) (e.g., immediate), Moloney's mouse leukemia virus (MoMLV), Rous sarcoma virus (RSV), and herpes simplex virus (HSV) (thymidine kinase). Typical promoters can drive high levels of transcription in a Tat-independent manner. This replacement reduces the likelihood of producing a virus capable of replication by recombination because the complete U3 sequence is not present in the viral production system. In certain embodiments, heterologous promoters have further advantages in controlling the manner in which the viral genome is transcribed. For example, a heterologous promoter may be inducible such that transcription of all or part of the viral genome occurs only in the presence of an inducer. Inducers include one or more compounds in which the host cells are cultured or physiological conditions such as temperature or pH.

[0082] In certain embodiments, the viral vector includes a TAR element. The term "TAR" refers to a "transactivation response" gene element located in the R region of the lentiviral LTR. This element interacts with the lentiviral transactivator (tat) gene element to enhance viral replication. However, this element is not required in embodiments where the U3 region of the 5' LTR is replaced by a heterologous promoter.

[0083] The "R region" refers to a region within a retroviral LTR that begins at the capping group start (i.e., the transcription start) and ends immediately before the poly(A) tract start. The R region is also defined as being adjacent to the U3 and U5 regions. During reverse transcription, the R region plays a role in enabling the transfer of nascent DNA from one end of the genome to the other.

[0084] In certain embodiments, the expression of heterologous sequences in a viral vector is increased by incorporating post-transcriptional regulatory elements, efficient polyadenylation sites, and, optionally, transcription termination signals into the vector. Various post-transcriptional regulatory elements can increase the expression of heterologous nucleic acids. Examples include the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE, Zufferey et al., 1999, J. Virol., 73:2886), the hepatitis B virus post-transcriptional regulatory element (HPRE) (Smith et al., Nucleic Acids Res. 26(21):4818-4827, 1998), (Liu et al., 1995, Genes Dev., 9:1766), etc. In certain embodiments, the vector includes a post-transcriptional regulatory element such as WPRE or HPRE. In certain embodiments, the vector lacks or does not include a post-transcriptional regulatory element such as WPRE or HPRE.

[0085] Elements that direct the efficient termination and polyadenylation of heterologous nucleic acid transcripts can increase heterologous gene expression. Transcription termination signals are generally found downstream of polyadenylation signals. In certain embodiments, the vector contains a polyadenylation signal 3' of the polynucleotide encoding the molecule to be expressed (e.g., a protein). The terms “poly(A) site” or “poly(A) sequence” refer to a DNA sequence that directs both the termination and polyadenylation of the nascent RNA transcript by RNA polymerase II. Polyadenylation sequences can enhance mRNA stability by adding a poly(A) tail to the 3' end of the coding sequence, thus contributing to improved translation efficiency. Certain embodiments may utilize BGHpA or SV40pA. In certain embodiments, a preferred embodiment of the expression construct includes a terminator element. These elements help increase transcript levels and minimize reading from the construct to other plasmid sequences.

[0086] In certain embodiments, the viral vector further comprises one or more insulator elements. The insulator elements may contribute to protecting the viral vector expression sequence, e.g., an effector element or an expressible element, from integration site effects that can be mediated by cis-acting elements present in the genomic DNA, resulting in the unregulated expression of the imported sequence (i.e., site effects, see, e.g., Burgess-Beusse et al., PNAS., USA, 99:16433, 2002 and Zhan et al., Hum. Genet., 109:471, 2001). In certain embodiments, the viral import vector comprises one or more insulator elements in the 3'LTR, and upon integration of the provirus into the host genome, the provirus replicates the 3'LTR, thereby comprising one or more insulators in both the 5'LTR and 3'LTR. Suitable insulators for use in specific embodiments include chicken β-globin insulators (see Chung et al., Cell 74:505, 1993, Chung et al., PNAS USA 94:575, 1997, and Bell et al., Cell 98:387, 1999), SP10 insulators (Abhyankar et al., JBC 282:36143, 2007), or other small CTCF-recognizing sequences that function as enhancer-blocking insulators (Liu et al., Nature Biotechnology, 33:198, 2015).

[0087] Beyond the foregoing description, a wide range of suitable expression vector types are known to those skilled in the art. These may include commercially available expression vectors designed for common recombination procedures, e.g., plasmids containing one or more reporter genes and regulatory elements necessary for the expression of the reporter genes in cells. Numerous vectors are commercially available from, for example, Invitrogen, Stratagene, Clontech, and others, and are described in numerous relevant guides. In certain embodiments, a suitable expression vector includes any plasmid, cosmid, or phage construct capable of supporting the expression of an encoded gene in mammalian cells, e.g., the pUC or Bluescript plasmid series.

[0088] Specific embodiments of the vectors disclosed herein include:

[0089] [Table 1]

[0090] Subcomponent sequences within larger vector sequences can be readily identified by those skilled in the art based on the content of this disclosure (see Figure 22). The nucleotides between identifiable subcomponents and the enumerated subcomponents reflect restriction enzyme recognition sites used in construct assembly (cloning), and in some cases, additional nucleotides do not convey identifiable function. These segments of the complete vector sequence can be adjusted based on different cloning strategies and / or vector use. Generally, short 6-nucleotide palindromic sequences reflect vector construction artifacts that are not important to vector function.

[0091] In certain embodiments, a vector having a capsid that crosses the blood-brain barrier (BBB) ​​(e.g., AAV) is selected. In certain embodiments, the vector is modified to include a capsid that crosses the BBB. Examples of AAVs with viral capsids that can cross the blood-brain barrier include AAV9 (Gombash et al., Front Mol Neurosci. 2014;7:81), AAVrh.10 ...

Claims

1. An artificial expression construct for selectively driving gene expression in a target central nervous system cell population, comprising: (i) an enhancer having the sequence shown in SEQ ID NO: 7 or a sequence having at least 95% sequence identity with the sequence shown in SEQ ID NO: 7; (ii) a promoter; and (iii) a coding sequence.

2. The artificial expression construct according to claim 1, wherein the coding sequence encodes a fluorescent protein.

3. The artificial expression construct according to claim 1, wherein the artificial expression construct is capsidized within a capsid that crosses the blood-brain barrier.

4. The artificial expression construct according to claim 3, wherein the capsid comprises PHP. eB, AAV9, AAVrh. 10, AAV-BR1, AAV-PHP.S, AAV-PHP. B, or AAV-PPS.

5. The artificial expression construct according to claim 1, wherein the artificial expression construct includes or encodes a skipping element.

6. The artificial expression construct according to claim 5, wherein the skipping element comprises a T2A peptide, a P2A peptide, an E2A peptide, an F2A peptide, or an internal ribosome entry site (IRES).

7. The artificial expression construct according to claim 1, wherein the artificial expression construct is located within a viral vector.

8. An administerable composition for use in a method for selectively expressing a gene in a population of neurons in vivo or in vitro, the method comprising selectively expressing the gene in the neuronal population by providing the administerable composition, comprising an artificial expression construct, to a sample or subject comprising the neuronal population in a sufficient dose and for a sufficient amount of time, wherein the artificial expression construct is: An enhancer having the sequence shown in Sequence ID No. 7 or a sequence having at least 95% sequence identity with the sequence shown in Sequence ID No. 7, promoter, and An administerable composition containing a code sequence.

9. The administerable composition according to claim 8, wherein the population of nerve cells comprises GABAergic neurons.

10. The administerable composition according to claim 8, wherein the population of nerve cells comprises Pvalb neurons.

Images